Johnson & Johnson: lung cancer drug approved
(CercleFinance.com) - Johnson & Johnson announces that the US FDA has approved Rybrevant in combination with Lazcluze for the first-line treatment of adults with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
This approval is based on the results of the phase 3 MARIPOSA study showing that this combination reduces the risk of disease progression or death by 30% compared to osimertinib, with a median duration of response of nine months longer.
This makes it the first and only multi-targeted, chemotherapy-free combination regimen demonstrated to be superior to osimertinib and approved for the first-line treatment of EGFR-mutated NSCLC.
Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.8 million deaths each year, with NSCLC accounting for 80% to 85% of all cases, the healthcare group points out.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This approval is based on the results of the phase 3 MARIPOSA study showing that this combination reduces the risk of disease progression or death by 30% compared to osimertinib, with a median duration of response of nine months longer.
This makes it the first and only multi-targeted, chemotherapy-free combination regimen demonstrated to be superior to osimertinib and approved for the first-line treatment of EGFR-mutated NSCLC.
Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.8 million deaths each year, with NSCLC accounting for 80% to 85% of all cases, the healthcare group points out.
Copyright (c) 2024 CercleFinance.com. All rights reserved.